Bharat Biotech Justifies Trial Site Shifts For Tetravalent Vaccine
Executive Summary
Trial-related challenges in India appear to have pushed vaccine maker Bharat Biotech towards opting for alternative sites for studies on its tetravalent vaccine. The firm says it has justified its position to the regulator, though some experts advise diligence in site selection.